Lumark

Lutetium (177Lu) Chloride is a radiopharmaceutical used in targeted therapy. It is administered intravenously and is manufactured by Idb Holland B.V. in the EU.

Lutetium (177Lu) Chloride is primarily used in targeted radiotherapy. This radiopharmaceutical is designed to deliver radiation directly to specific cells, which may help in managing certain conditions. It is often explored in contexts where precise targeting is beneficial, such as in some cancer treatments.

Lutetium (177Lu) Chloride works by emitting radiation that can affect the targeted cells. Common effects may include localized responses due to the radiation. Patients should discuss potential effects with their healthcare provider.

Handling Lutetium (177Lu) Chloride requires careful consideration due to its radioactive nature. It should only be administered by trained professionals in a controlled environment. Proper safety measures must be followed to ensure the safe handling and disposal of the substance.

Lutetium (177Lu) Chloride may interact with other medications or treatments, particularly those involving radiation or certain chemotherapy agents. Patients should inform their healthcare provider about all current treatments to avoid potential interactions.